Tissue Regenix Group Regulatory News (TRX)

Tissue Regenix Group plc

("Tissue Regenix" or "The Group")

DermaPure® breaks through $1m sales mark

York, 20 January 2016 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company announces its dCELL® woundcare product DermaPure® has now surpassed the $1m sales mark, following its commercialisation in the US. DermaPure® was issued the Medicare 'Q' code for reimbursement in November 2014, which became effective as of January 1st 2015, and is now available to almost 65% of Medicare beneficiaries, spanning 31 states.

The product is primarily aimed at the treatment of chronic wounds associated with diabetes. Approximately 10% of the American population are currently suffering from Type I or Type 2 diabetes, making the prevalence of hard to heal wounds, a common side effect of the disease, increase rapidly. In addition, DermaPure® is being used in a number of other varied clinical settings, treating conditions from pressure ulcers to frostbite. It is expected that Tissue Regenix, Woundcare Inc. will now develop this same dCELL® technology into products addressing other applications.

Greg Bila, President of Tissue Regenix Woundcare, Inc. commented, "Since launch in 2014, the uptake of DermaPure® within a competitive marketplace has been highly encouraging and we are thrilled to announce the first $1m of sales. We are finding that it is the intrinsic qualities of DermaPure® which make it effective and differentiate it from other products available. Unlike cell based products, DermaPure® signals the body to redirect the patient's own cells to the affected area, allowing the body to regenerate healthy tissue. I would like to thank our clinical affairs and sales teams, whose hard work has allowed us to reach this milestone, and look forward to seeing continued momentum in the coming year."

For more information:

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

 Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.